Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
A major obstacle hindering the market's growth is the ongoing deficit in standardization and compatibility across various NGS informatics systems, making collaborative data exchange difficult. Along with worries regarding the privacy and security of sensitive information, this fragmentation creates a substantial barrier to achieving smooth operations and broad integration throughout the worldwide genomics landscape.
Market Driver
The rapid expansion in the size and complexity of genomic information is a central driver for the Global Next Generation Sequencing (NGS) Informatics Market. With falling sequencing expenses and rising processing capacities, medical professionals and scientists are producing record volumes of raw data, encompassing transcriptome, exome, and whole-genome sequences. Efficiently storing, organizing, and evaluating these massive datasets necessitates advanced informatics platforms capable of processing petabytes of data. This flood of information accelerates the need for automated applications dedicated to annotation, variant calling, alignment, and quality assurance. Highlighting this ongoing data boom, a November 2025 blog post by Illumina titled 'Leadership Perspectives: Illumina leads the industry in genomic AI' reported that the sector currently produces more than 40 billion gigabytes of genomic data annually.The market is additionally stimulated by the growing incorporation of artificial intelligence (AI), cloud technologies, and sophisticated data analytics into NGS informatics. These innovations play a crucial role in deriving valuable biological conclusions from intricate genomic data, increasing diagnostic precision, and automating tedious analytical procedures.
Cloud platforms provide adaptable frameworks for processing and storing data, fostering shared research initiatives, while AI and machine learning models improve disease forecasting and variant assessment by detecting nuanced trends in extensive genomic groups. Illustrating the rising scope of AI-assisted genomics, an April 14, 2026, Stock Titan report detailed an Illumina partnership with the Center for Data-Driven Discovery in Biomedicine that utilized cloud, AI, and software systems to analyze 100,000 pediatric whole genomes. More broadly, the global genomics field is steadily expanding, as evidenced by the National Human Genome Research Institute's March 2024 'Fiscal Year 2025 Congressional Justification,' which outlined an estimated budget of $663.7 million for genomics research in the 2025 fiscal year.
Market Challenge
The sustained absence of compatibility and standardization across various platforms and tools remains a major hurdle restricting the expansion of the Global Next Generation Sequencing (NGS) Informatics Market. This disconnected landscape makes it difficult for pharmaceutical firms, diagnostic labs, and research centers to collaborate and share information effectively. Because uniform data structures are missing, organizations must perform labor-intensive custom integrations that drive up operational expenses and extend developmental timelines. Ultimately, this inefficiency delays the process of turning genomic discoveries into practical medical treatments.Furthermore, prevalent anxieties regarding the security and privacy of highly sensitive genomic data exacerbate these challenges. Such worries prompt rigorous regulatory frameworks and hesitant information sharing, which obstruct the fluid movement and application of data. Facilities remain reluctant to implement NGS informatics platforms that do not feature stringent privacy safeguards, thereby restricting broader market adoption. Highlighting this issue, the 2025 Lab of the Future survey by the Pistoia Alliance revealed that 49% of labs viewed data ontologies and standards as a primary obstacle keeping information from becoming Findable, Accessible, Interoperable, and Reusable (FAIR), a barrier that ultimately suppresses innovation and the growth of emerging services within the NGS informatics field.
Market Trends
The capacity to integrate holistic multi-omics data is reshaping the global Next Generation Sequencing informatics landscape by fostering a thorough comprehension of biological networks beyond isolated data categories. This movement focuses on merging metabolomic, proteomic, transcriptomic, and genomic information to construct an extensive molecular portrait of a patient, a critical step for classifying treatments and understanding diseases. Consequently, NGS informatics systems are advancing to handle and evaluate these vast, varied datasets, paving the way for more profound biological discoveries. Highlighting the strategic value of combined omics analysis, Illumina, Inc. disclosed its intent to purchase SomaLogic for $350 million in a June 23, 2025, press release titled 'Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy,' aiming to incorporate aptamer-based tools to enhance multiomics biomarker detection.Another vital trend is the growing incorporation of Next Generation Sequencing informatics into clinical diagnostics, transitioning its use from mostly research-oriented purposes to standard patient healthcare. This shift requires deploying sophisticated analytical programs and software in hospitals and testing labs for tailored treatment strategies, pathogen identification, and genetic disorder screening. Transitioning into these clinical environments necessitates intuitive, reliable informatics systems capable of providing precise and swift data to guide critical medical choices. Emphasizing the substantial medical and financial benefits of this integration, a December 11, 2025, Illumina press release titled 'Illumina and MyOme strike collaboration deal including strategic investment to support MyOme's clinical trial that could save US healthcare $200 billion annually' noted that widespread use of clinical whole-genome sequencing paired with AI-driven risk frameworks could save the system over $200 billion each year.
Key Market Players
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- PerkinElmer, Inc.
- SOPHiA GENETICS SA
- Precigen, Inc.
- QIAGEN N.V.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Eagle Genomics Limited
- BGI Genomics Co., Ltd.
Report Scope
In this report, the Global Next Generation Sequencing (NGS) Informatics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Next Generation Sequencing (NGS) Informatics Market, By Products & Services:
- Storage and Computing Tools
- Commercial Data Analysis
- Data Interpretation and Reporting Tools
- Next Generation Sequencing (NGS) Laboratory Information Management Systems (LIMS)
Next Generation Sequencing (NGS) Informatics Market, By Application:
- Drug Discovery
- Genetic Screening
- Disease Diagnosis
- Others
Next Generation Sequencing (NGS) Informatics Market, By End User:
- Hospitals and Diagnostic Centers
- Pharmaceutical and Biotechnology Companies
- Academic
- Research Institutions
Next Generation Sequencing (NGS) Informatics Market, By Region:
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Sequencing (NGS) Informatics Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- PerkinElmer, Inc.
- SOPHiA GENETICS SA
- Precigen, Inc.
- QIAGEN N.V.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Eagle Genomics Limited
- BGI Genomics Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | May 2026 |
| Forecast Period | 2025 - 2031 |
| Estimated Market Value ( USD | $ 5.73 Billion |
| Forecasted Market Value ( USD | $ 19.74 Billion |
| Compound Annual Growth Rate | 22.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |


